Full Press Release Details
Ascentage Pharma to Participate in Three Upcoming
Investor Conferences
ROCKVILLE, MD. and SUZHOU, China, May 12, 2026
-- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) ("Ascentage Pharma" or the "Company"), a
global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated
therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate in
three upcoming investor conferences.
The webcasts for the fireside chat and presentation
can be accessed by visiting the Events page in the Investor Relations section
of Ascentage Pharma's website.
About Ascentage Pharma Group International
Ascentage Pharma Group International (NASDAQ:
AAPG; HKEX: 6855) ("Ascentage Pharma" or the "Company") is a global, commercial stage,
integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to
address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors
targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.
The Company's first approved product, Olverembatinib,
is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase
(CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first-
and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently
conducting an FDA-cleared global registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as global registrational
Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.
The Company's second approved product, Lisaftoclax,
is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China's National
Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) who have previously received at least one systemic therapy including Bruton's tyrosine kinase (BTK) inhibitors. The Company
is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK
inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2
study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA-cleared
GLORA-4 study in patients with newly diagnosed higher risk MDS.
Leveraging its robust R&D capabilities, Ascentage
Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships
with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition
to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National
Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All
statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements
that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future
events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties
as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled "Risk factors"
and "Cautionary note regarding forward-looking statements" in its Annual Report on Form 20-F for the year ended December
31, 2025, filed with the SEC on April 29, 2026, the sections headed "Forward-looking Statements" and "Risks
Factors" in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other
filings with the SEC and/or The Stock Exchange of Hong Kong Limited, where the Company's ordinary shares are listed,
it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially
different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this
presentation do not constitute profit forecast by the Company's management.
As a result of these factors, you should not rely
on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are
based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak
only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
Stephanie Carrington